Search research articles
Contact Us
Filters
Showing results (81-90 of 118) with videos related to
Page
of 12
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
June 11, 2024
EBCC-14 manifesto: Addressing disparities in access to innovation for patients with metastatic breast cancer across Europe
Michail Ignatiadis, Fiorita Poulakaki, Tanja Spanic, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 31, 2013
New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951
Thierry Gorlia, Jean-Yves Delattre, Alba A Brandes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2008
Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
Eric Raymond, Alba A Brandes, Christian Dittrich, et al.
Acta Neuropathologica
|
July 20, 2012
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status
Pierre Bady, Davide Sciuscio, Annie-Claire Diserens, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 2, 2014
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study
Sophie Postel-Vinay, Laurence Collette, Xavier Paoletti, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 18, 2010
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
Patrick Schöffski, Jean-Yves Blay, Jacques De Greve, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 20, 2007
Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study
Murielle E L Mauer, Martin J B Taphoorn, Andrew Bottomley, et al.
International Journal of Technology Assessment in Health Care
|
April 23, 2020
The fourth edition of the European Network for Health Technology Assessment Forum: highlights and outcomes
Giovanni Tafuri, Chantal Bélorgey, Carlo Favaretti, et al.
Cancer Treatment Reviews
|
September 3, 2025
Overcoming the barriers to treatment of rare cancer patients in the era of precision oncology: A call to action
Winette T A van der Graaf, Nina S Heiss, Carolyn L Hynes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 18, 2010
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
Martin J van den Bent, Hendrikus J Dubbink, Yannick Marie, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 118) with videos related to
Sort By:
Page
of 12
European Journal of Cancer (Oxford, England : 1990)
|
June 11, 2024
EBCC-14 manifesto: Addressing disparities in access to innovation for patients with metastatic breast cancer across Europe
Michail Ignatiadis, Fiorita Poulakaki, Tanja Spanic, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 31, 2013
New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951
Thierry Gorlia, Jean-Yves Delattre, Alba A Brandes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2008
Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
Eric Raymond, Alba A Brandes, Christian Dittrich, et al.
Acta Neuropathologica
|
July 20, 2012
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status
Pierre Bady, Davide Sciuscio, Annie-Claire Diserens, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 2, 2014
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study
Sophie Postel-Vinay, Laurence Collette, Xavier Paoletti, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 18, 2010
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
Patrick Schöffski, Jean-Yves Blay, Jacques De Greve, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 20, 2007
Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study
Murielle E L Mauer, Martin J B Taphoorn, Andrew Bottomley, et al.
International Journal of Technology Assessment in Health Care
|
April 23, 2020
The fourth edition of the European Network for Health Technology Assessment Forum: highlights and outcomes
Giovanni Tafuri, Chantal Bélorgey, Carlo Favaretti, et al.
Cancer Treatment Reviews
|
September 3, 2025
Overcoming the barriers to treatment of rare cancer patients in the era of precision oncology: A call to action
Winette T A van der Graaf, Nina S Heiss, Carolyn L Hynes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 18, 2010
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
Martin J van den Bent, Hendrikus J Dubbink, Yannick Marie, et al.
Page
of 12